Abstracts tagged "inflammation and monocytes"

Abstract Number: 1000 • 2018 ACR/ARHP Annual Meeting
Surface Adenosine Monophosphate Deaminase 2 As a Novel Regulator Modifying Ectonucleotidase-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Lisa Ehlers^1,2, Aditi Kuppe^1,2, Alexandra Damerau^3,4, Yuling Chen^1,2, Cindy Strehl^3,5, Marieluise Kirchner⁶, Frank Buttgereit¹ and Timo Gaber^3,5, ¹Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ²German Rheumatism Research Centre Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁵Deutsches Rheuma Forschungszentrum (DRFZ) Berlin, Berlin, Germany, ⁶BIH Core Facility Proteomics, Max Delbrück Centre for Molecular Medicine, Berlin, Germany
Background/Purpose: Extracellular ATP and adenosine are potent immunomodulatory molecules that accumulate in states of inflammation. ATP/ADP are released from damaged or stressed cells and sequentially…
Abstract Number: 2120 • 2018 ACR/ARHP Annual Meeting
CD47- Signal Regulatory Protein Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus
Jin Kyun Park¹, Ye Ji Lee², Ji Soo Park³, Eun Young Lee⁴, Eun Bong Lee⁴ and Yeong Wook Song⁵, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Department of Immunology, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ³Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Korea, Seoul, Korea, Republic of (South), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁵Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
CD47-Signal Regulatory Protein-Alpha Interaction Potentiates Proinflammatory Response in Systemic Lupus Erythematosus.Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease mediated by unbalanced activation of…
Abstract Number: 302 • 2017 ACR/ARHP Annual Meeting
From Monocytes to Macrophages: the Pathogeneses of Spontaneous Inflammatory Arthritis in CD11c-Flip-KO (HUPO) Mice
Qi Quan Huang¹, Renee E. Doyle², Philip J. Homan¹, Harris Perlman³, Deborah R. WInter³ and Richard M. Pope², ¹Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: We have generated a CD11c-Flip-KO mouse line (HUPO) that spontaneously develops erosive arthritis with incidence 70-80% at age ≥ 20 weeks. This study aimed…
Abstract Number: 1142 • 2013 ACR/ARHP Annual Meeting
Distinct Pathways Of Ly6C^hi Monocyte Development Identified By a Novel Dual-Reporter Murine Myeloid Progenitor Cell Line
Pui Lee¹, David Sykes², Sarah Ameri³, Demetrios Kalaitzidis², Peter A. Nigrovic⁴ and Astrid Cardona⁵, ¹Boston Children's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA, ⁵University of Texas - San Antonio, San Antonio, MA
Background/Purpose: Monocytes are essential to innate immunity but also propagate the inflammatory response in autoimmune arthritis and crystal arthropathies. Development of inflammatory monocytes (Ly6Chi CCR2+)…
Abstract Number: 1803 • 2012 ACR/ARHP Annual Meeting
Chemokine-Like Receptor 1 (CMKLR1), a G Protein Coupled Receptor Expressed On Proinflammatory Monocytes in Arthritis, Is Negatively Regulated by GRK3
D. Stephen Serafin¹, Roman Timoshchenko¹, Marcus W. McGinnis² and Teresa K. Tarrant³, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Thurston Arthritis Research Center, University of North Carolina Sch of Med, Chapel Hill, NC, ³Medicine/Rheumatology, UNC School of Medicine, Chapel Hill, NC
Background/Purpose: Chemokine-like receptor 1 (CMKLR1) is a G protein coupled receptor (GPCR) expressed by inflammatory monocytes that are pathogenic in human diseases such as psoriasis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.